Skip to content
Arixtra(fondaparinux sodium)
Arixtra (fondaparinux sodium) is an oligosaccharide pharmaceutical. Fondaparinux sodium was first approved as Arixtra on 2001-12-07. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat myocardial infarction, pulmonary embolism, unstable angina, and venous thrombosis. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Arixtra (generic drugs available since 2011-07-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fondaparinux sodium
Tradename
Company
Number
Date
Products
ARIXTRAMylanN-021345 RX2001-12-07
4 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
arixtraNew Drug Application2020-08-20
fondaparinux sodiumANDA2022-12-23
fondaparinux sodiumANDA2022-12-23
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pulmonary embolismEFO_0003827D011655I26
venous thrombosisHP_0004936D020246I82.40
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AX: Other antithrombotic agents in atc
— B01AX05: Fondaparinux
HCPCS
Code
Description
J1652
Injection, fondaparinux sodium, 0.5 mg
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Venous thromboembolismD054556EFO_0004286I741141612
Pulmonary embolismD011655EFO_0003827I261221510
ThromboembolismD013923HP_0001907—16119
Renal insufficiencyD051437HP_0000083N191——113
Acute coronary syndromeD054058EFO_0005672——1113
Replacement arthroplasty kneeD019645———1—1
ThrombocytopeniaD013921HP_0001873D69.6———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Venous thrombosisD020246HP_0004936I82.40126—715
NeoplasmsD009369C80——1—12
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ovarian neoplasmsD010051EFO_0003893C5611———2
Respiratory insufficiencyD012131HP_0002093J96.9—1———1
Embolism and thrombosisD016769—1———1
Viral pneumoniaD011024EFO_0007541J12.9—1———1
Atrial fibrillationD001281EFO_0000275I48.0—1———1
Myocardial infarctionD009203EFO_0000612I21—1———1
Coronary diseaseD003327—1———1
Endometrial neoplasmsD016889EFO_0004230—1———1
SarcomaD012509—1———1
Fallopian tube neoplasmsD005185—1———1
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ThrombosisD0139271———12
Non-small-cell lung carcinomaD0022891————1
Morbid obesityD009767EFO_00010741————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AtaxiaD001259R27.0————22
Cardiovascular diseasesD002318EFO_0000319I98————22
Covid-19D000086382U07.1————11
Esophageal neoplasmsD004938C15————11
Lung neoplasmsD008175C34.90————11
Coronary artery bypassD001026EFO_0003776————11
Kidney diseasesD007674EFO_0003086N08————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFONDAPARINUX SODIUM
INNfondaparinux sodium
Description
Fondaparinux is a synthetic pentasaccharide which, apart from the O-methyl group at the reducing end of the molecule, consists of monomeric sugar units which are identical to a sequence of five monomeric sugar units that can be isolated after either chemical or enzymatic cleavage of the polymeric glycosaminoglycans heparin and heparan sulfate. It has a role as an anticoagulant. It is an amino sugar, an oligosaccharide sulfate and a pentasaccharide derivative. It is functionally related to a normethylfondaparinux. It is a conjugate acid of a fondaparinux(10-).
Classification
Oligosaccharide
Drug classantihrombotic indirect selective synthetic factor Xa inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO[C@H]1O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]2O[C@@H](C(=O)[O-])[C@@H](O[C@H]3O[C@H](COS(=O)(=O)[O-])[C@@H](O[C@@H]4O[C@H](C(=O)[O-])[C@@H](O[C@H]5O[C@H](COS(=O)(=O)[O-])[C@@H](O)[C@H](O)[C@H]5NS(=O)(=O)[O-])[C@H](O)[C@H]4O)[C@H](OS(=O)(=O)[O-])[C@H]3NS(=O)(=O)[O-])[C@H](O)[C@H]2OS(=O)(=O)[O-])[C@H](O)[C@H]1NS(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Identifiers
PDB—
CAS-ID104993-28-4
RxCUI321208
ChEMBL IDCHEMBL1200644
ChEBI ID—
PubChem CID5282448
DrugBankDB00569
UNII IDX0Q6N9USOZ (ChemIDplus, GSRS)
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
462
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Q9UC78
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,017 documents
View more details
Safety
Black-box Warning
Black-box warning for: Arixtra, Fondaparinux sodium, Fondaparinux sodium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
122,605 adverse events reported
View more details